Evidence map›Paper›PMID 19859732›Full record

ReviewVirchows Archiv : an international journal of pathology2010

Precursors of endometrial and ovarian carcinoma.

Robert J Kurman, Thomas G McConnell

Abstract readReview
PubMed Publisher
In one paragraph

Review in Virchows Archiv : an international journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Papillary mucinous metaplasia: a distinct precursor of mucinous adenocarcinoma of the endometrium.International journal of clinical and experimental pathology · 2022
    Article
  3. Review
  4. Article
  5. Article
  6. Clinical significance of microRNA expressions in diagnosing uterine cancer and predicting lymph node metastasis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Article
  7. Article
  8. The duplicitous origin of ovarian cancer.Rambam Maimonides medical journal · 2013
    Article
  9. Article
  10. Expression of αV-integrins in uterine serous papillary carcinomas; implications for targeted therapy with intetumumab (CNTO 95), a fully human antagonist anti-αV-integrin antibody.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Robert J KurmanDepartment of Gynecology and Obstetrics, The Johns Hopkins University School of Medicine and Hospital, Baltimore, MD, USA. rkurman@jhmi.edu
Thomas G McConnell

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review discusses precursor lesions of endometrial and ovarian carcinoma with an emphasis on the unique molecular alterations that have led to the development of binary classification schemes for tumors of both the endometrium and ovary. While such a system is well established for endometrial carcinoma, only recently has a binary classification scheme been proposed for ovarian carcinoma. For both, the morphologic and molecular genetic-defining characteristics of their respective precursor lesions are described in detail. Furthermore, similarities and differences of the precursor lesions of specific tumors of these two genital tract organs are also addressed with a brief discussion of the clinical implications of their diagnosis.

Indexed as

Adenocarcinoma, MucinousCarcinoma, EndometrioidEndometrial HyperplasiaEndometrial NeoplasmsFemaleHumansOvarian NeoplasmsPrecancerous ConditionsTumor Suppressor Protein p53Tumor Suppressor Protein p53

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.